Single-Drug immunotherapy shows promise for advanced lung cancer

This study looks at how well the immunotherapy drug ivonescimab works when used alone as the first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive) and no targetable gene mutations. About 265 participants will receive ivonescimab every three weeks, and researchers will track how long the cancer stays under control and any side effects in real-world clinic settings. The goal is to see if this single-drug approach can be an effective option without needing chemotherapy.